Home › Funds › Caligan Partners LP › LBRX
Caligan Partners LP position in LBRX
LB PHARMACEUTICALS INC · Health Care
Caligan Partners LP reported holding 1,509,621 shares of LBRX (LB PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$49.6M, representing 3.04% of its reported portfolio and ranking #11 among its reported holdings. Caligan Partners LP has disclosed LBRX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's LBRX position evolved
Caligan Partners LP first disclosed a stake in LBRX in Q1 2026 at 1,438,070 shares (US$34.6M). The position peaked in Q3 2026 at 1,509,621 shares, worth US$49.6M. Across 3 filings, Caligan Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,509,621 shares valued at US$49.6M — an increase of 71,551 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.44M | $34.63M | New |
| Q2 2026 | 1.44M | $46.67M | Hold |
| Q3 2026 | 1.51M | $49.62M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LBRX and 13F data
LBRX (LB PHARMACEUTICALS INC) is a Health Care company. 102 other funds we track also report a position in LBRX — the largest reported positions include Deep Track Capital, LP (US$128.7M), RA CAPITAL MANAGEMENT, L.P. (US$84.8M), Spruce Street Capital LP (US$53.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LBRX
- Deep Track Capital, LP 3.35M sh · $128.68M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 2.21M sh · $84.77M · Q3 2026
- Spruce Street Capital LP 1.40M sh · $53.86M · Q3 2026
- Commodore Capital LP 1.28M sh · $49.21M · Q3 2026
- Trails Edge Capital Partners, LP 1.15M sh · $44.11M · Q3 2026
- Nantahala Capital Management, LLC 1.07M sh · $41.23M · Q3 2026
- Vivo Capital, LLC 800.00K sh · $30.70M · Q3 2026
- TCG Crossover Management, LLC 765.05K sh · $29.36M · Q3 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 741.41K sh · $28.46M · Q3 2026
- Bellevue Group AG 715.51K sh · $27.46M · Q3 2026
- Nan Fung Group Holdings Ltd 630.66K sh · $24.20M · Q3 2026
- Integral Health Asset Management, LLC 470.00K sh · $18.04M · Q3 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held LBRX?
Caligan Partners LP has disclosed LBRX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Caligan Partners LP's current position in LBRX?
As of Q3 2026, Caligan Partners LP holds 1.51M shares of LBRX (LB PHARMACEUTICALS INC), valued at $49.62M, representing 3.04% of its reported portfolio and ranking #11.
Has Caligan Partners LP been buying or selling LBRX?
In the latest 13F filing (Q3 2026), Caligan Partners LP increased its position in LBRX. The position peaked in Q3 2026 at 1.51M shares.
Which other funds hold LBRX?
Other major institutional holders of LBRX include Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., Spruce Street Capital LP, among 102 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.